PL3177640T3 - Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania - Google Patents
Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystaniaInfo
- Publication number
- PL3177640T3 PL3177640T3 PL15829652T PL15829652T PL3177640T3 PL 3177640 T3 PL3177640 T3 PL 3177640T3 PL 15829652 T PL15829652 T PL 15829652T PL 15829652 T PL15829652 T PL 15829652T PL 3177640 T3 PL3177640 T3 PL 3177640T3
- Authority
- PL
- Poland
- Prior art keywords
- agents
- methods
- high affinity
- affinity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462035316P | 2014-08-08 | 2014-08-08 | |
US201562150789P | 2015-04-21 | 2015-04-21 | |
PCT/US2015/044356 WO2016022994A2 (en) | 2014-08-08 | 2015-08-07 | High affinity pd-1 agents and methods of use |
EP15829652.5A EP3177640B1 (en) | 2014-08-08 | 2015-08-07 | High affinity pd-1 agents and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3177640T3 true PL3177640T3 (pl) | 2020-11-02 |
Family
ID=55264785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL15829652T PL3177640T3 (pl) | 2014-08-08 | 2015-08-07 | Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania |
Country Status (13)
Country | Link |
---|---|
US (4) | US9546206B2 (pl) |
EP (2) | EP3177640B1 (pl) |
JP (1) | JP6945444B2 (pl) |
CN (1) | CN107108707A (pl) |
CA (1) | CA2994927A1 (pl) |
CY (1) | CY1123385T1 (pl) |
DK (1) | DK3177640T3 (pl) |
ES (1) | ES2819451T3 (pl) |
HR (1) | HRP20201153T1 (pl) |
HU (1) | HUE050406T2 (pl) |
PL (1) | PL3177640T3 (pl) |
PT (1) | PT3177640T (pl) |
WO (1) | WO2016022994A2 (pl) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016022994A2 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
BR112017006203A2 (pt) * | 2014-09-30 | 2018-05-02 | Intervet International B.V. | anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune. |
SG11201703760WA (en) | 2014-11-25 | 2017-06-29 | Bristol Myers Squibb Co | Novel pd-l1 binding polypeptides for imaging |
WO2016086036A2 (en) | 2014-11-25 | 2016-06-02 | Bristol-Myers Squibb Company | Methods and compositions for 18f-radiolabeling of biologics |
BR112017018770A2 (pt) | 2015-03-02 | 2018-04-17 | Innovative Cellular Therapeutics CO., LTD. | redução da tolerância imunológica induzida por pd-l1 |
EP3875477A1 (en) | 2015-04-17 | 2021-09-08 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
EA201890285A1 (ru) | 2015-07-13 | 2018-08-31 | Сайтомкс Терапьютикс, Инк. | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения |
CN116059219A (zh) | 2015-07-16 | 2023-05-05 | 比奥克斯塞尔医疗股份有限公司 | 一种使用免疫调节治疗癌症的新颖方法 |
NZ738950A (en) | 2015-08-07 | 2023-03-31 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
ES2907486T3 (es) * | 2015-09-24 | 2022-04-25 | Univ North Carolina Chapel Hill | Métodos y composiciones para reducir metástasis |
BR112018070934A2 (pt) | 2016-04-15 | 2019-02-26 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas |
JP2019521643A (ja) | 2016-04-15 | 2019-08-08 | アルパイン イミューン サイエンシズ インコーポレイテッド | Cd80バリアント免疫調節タンパク質およびその使用 |
US11352413B2 (en) * | 2016-05-17 | 2022-06-07 | Albert Einstein College Of Medicine | Engineered PD-1 variants |
WO2017210335A1 (en) * | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
EP3463486A1 (en) | 2016-06-01 | 2019-04-10 | Bristol-Myers Squibb Company | Pet imaging with pd-l1 binding polypeptides |
RU2656181C1 (ru) * | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
WO2018027252A1 (en) * | 2016-08-11 | 2018-02-15 | The Council Of The Queensland Institute Of Medical Research | Immune-modulating compounds |
WO2018067361A1 (en) * | 2016-10-04 | 2018-04-12 | The Curators Of The University Of Missouri | Peptides for molecular detection of pd-l1 |
PL3445787T3 (pl) | 2016-10-07 | 2021-05-31 | TCR2 Therapeutics Inc. | Kompozycje i sposoby reprogramowania receptorów limfocytów t przy użyciu białek fuzyjnych |
AU2017355401A1 (en) | 2016-11-02 | 2019-05-02 | Jounce Therapeutics, Inc. | Antibodies to PD-1 and uses thereof |
CA3043329A1 (en) | 2016-11-09 | 2018-05-17 | Healthtell Inc. | Coatings with tunable amine density |
CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
MY191926A (en) | 2016-12-01 | 2022-07-18 | Regeneron Pharma | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
CN110536693B (zh) * | 2017-01-05 | 2023-12-22 | 卡尔医学有限公司 | Pd1-41bbl融合蛋白及使用其的方法 |
US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
KR102581439B1 (ko) | 2017-01-05 | 2023-09-21 | 카 메디컬 리미티드 | Sirp알파-41bbl 융합 단백질 및 이의 이용 방법 |
WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
EP3580238A1 (en) | 2017-02-10 | 2019-12-18 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
EP3589295A4 (en) | 2017-02-28 | 2020-11-04 | Endocyte, Inc. | COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY |
EP3596115A1 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
BR112019018747A2 (pt) | 2017-03-16 | 2020-05-05 | Alpine Immune Sciences Inc | proteínas imunomoduladoras variantes de cd80 e usos das mesmas |
CN110636855A (zh) * | 2017-03-28 | 2019-12-31 | 俄亥俄州创新基金会 | 人pd1肽疫苗及其用途 |
WO2018192443A1 (zh) * | 2017-04-17 | 2018-10-25 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种多肽及其应用 |
WO2018195339A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
JP2020521759A (ja) * | 2017-05-26 | 2020-07-27 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 免疫トレランスを調節するための多機能性の抗体−リガンド・トラップ |
JP7304846B2 (ja) | 2017-07-24 | 2023-07-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗cd8抗体およびその使用 |
US20200206344A1 (en) * | 2017-08-21 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Methods for modulating the interaction between ews-fli1 and baf complexes |
US11753458B2 (en) | 2017-10-10 | 2023-09-12 | Alpine Immune Sciences, Inc. | CTLA-4 variant immunomodulatory proteins and uses thereof |
CN111712515A (zh) | 2017-10-18 | 2020-09-25 | 高山免疫科学股份有限公司 | 变体icos配体免疫调节蛋白及相关组合物和方法 |
JP7308191B2 (ja) | 2017-10-18 | 2023-07-13 | フォーティ セブン, インコーポレイテッド | 抗cd47剤ベースの卵巣癌療法 |
CN107916255B (zh) * | 2017-11-16 | 2021-06-04 | 复旦大学 | Pdl-1基因靶向特异性甲基化表观遗传修饰抗肿瘤分子及其用途 |
TW201940182A (zh) | 2018-01-22 | 2019-10-16 | 美商安德賽特公司 | Car t 細胞之使用方法 |
CN108794619B (zh) * | 2018-05-31 | 2021-09-17 | 郑州大学 | 一种高亲和pd-1蛋白突变体 |
WO2019227490A1 (en) * | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
JP2021531265A (ja) * | 2018-07-11 | 2021-11-18 | カール メディカル リミテッド | Pd1−4−1bblバリアント融合タンパク質及びその使用方法 |
JP2021529547A (ja) | 2018-07-11 | 2021-11-04 | カール メディカル リミテッド | SIRPα−4−1BBLバリアント融合タンパク質及びその使用方法 |
CN108997492B (zh) * | 2018-07-19 | 2022-04-12 | 海珂分子(北京)科技有限责任公司 | 高亲和力的pd1胞外区突变体多肽及相关融合蛋白 |
TWI815964B (zh) * | 2018-09-14 | 2023-09-21 | 李蘭 史丹佛學院理事會 | sPD-1變異體–FC融合蛋白 |
CN113677691A (zh) * | 2018-11-14 | 2021-11-19 | 库博科学公司 | 选择功能界面模拟物的方法及其组合物 |
KR20210093303A (ko) | 2018-11-21 | 2021-07-27 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 아데노바이러스 및 아데노바이러스의 사용 방법 |
CN111100199B (zh) * | 2018-12-29 | 2021-02-12 | 北京百普赛斯生物科技股份有限公司 | 一种荧光素标记的蛋白四聚体及其制备方法与应用 |
CN111714618A (zh) * | 2019-03-22 | 2020-09-29 | 广东香雪精准医疗技术有限公司 | T细胞和高亲和力pd-1融合蛋白的组合 |
CN110054701B (zh) * | 2019-04-17 | 2022-12-27 | 中国医学科学院血液病医院(血液学研究所) | 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用 |
EP3911671A1 (en) | 2019-04-29 | 2021-11-24 | Mayo Foundation for Medical Education and Research | Multivalent pd-l1 binding compounds for treating cancer |
AU2020265749A1 (en) | 2019-05-01 | 2022-01-06 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods |
MX2021013219A (es) | 2019-05-01 | 2022-02-17 | Juno Therapeutics Inc | Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos. |
US11613564B2 (en) | 2019-05-31 | 2023-03-28 | ALX Oncology Inc. | Methods of treating cancer |
CN112279922B (zh) * | 2019-07-22 | 2023-07-28 | 南京助天中科科技发展有限公司 | 一种吞噬细胞嵌合抗原受体及其应用 |
MX2022005535A (es) * | 2019-11-14 | 2022-07-27 | Ludwig Inst For Cancer Res Ltd | Composiciones y metodos para inmunoterapia. |
KR102623161B1 (ko) * | 2020-10-08 | 2024-01-09 | 고려대학교 산학협력단 | Pd-l1 친화도가 증가된 pd-1 변이체 |
US20230183318A1 (en) * | 2020-05-06 | 2023-06-15 | Korea University Research And Business Foundation | Pd-1 variants having increased pd-l1 affinity |
CN116234558A (zh) | 2020-06-26 | 2023-06-06 | 朱诺治疗学有限公司 | 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法 |
WO2022104043A1 (en) * | 2020-11-13 | 2022-05-19 | Ludwig Institute For Cancer Research Ltd | Pd-1 decoy variants for immunotherapy |
CN112999368A (zh) * | 2021-04-09 | 2021-06-22 | 广东药康生物科技有限公司 | 人源化模型进行药效评价方法的建立 |
WO2023097313A1 (en) * | 2021-11-26 | 2023-06-01 | Vita Therapeutics, Inc. | Immune cell therapy of pd-l1 positive cancers |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル. グラハム,フランク | 遺伝子治療のためのアデノウイルスベクター |
RU2162342C2 (ru) | 1993-10-25 | 2001-01-27 | Кэнджи Инк. | Рекомбинантный аденовирусный вектор и способы его применения |
JPH07291996A (ja) * | 1994-03-01 | 1995-11-07 | Yuu Honshiyo | ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするdna、そのdnaからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物 |
EP1083231A1 (en) | 1999-09-09 | 2001-03-14 | Introgene B.V. | Smooth muscle cell promoter and uses thereof |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
US7169874B2 (en) | 2001-11-02 | 2007-01-30 | Bausch & Lomb Incorporated | High refractive index polymeric siloxysilane compositions |
HUE026039T2 (en) * | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies programmed for death ligand 1 (PD-L1) |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
DK2350129T3 (en) * | 2008-08-25 | 2015-08-31 | Amplimmune Inc | PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF |
HUE028582T2 (en) | 2008-11-28 | 2016-12-28 | Univ Emory | Method for determining the efficacy of PD-1 antagonists |
US20110189743A1 (en) * | 2009-10-06 | 2011-08-04 | Bio Architecture Lab, Inc. | Microbial systems for producing commodity chemicals |
EP2910572B1 (en) * | 2010-11-11 | 2017-09-06 | Versitech Limited | Soluble pd-1 variants, fusion constructs, and uses thereof |
JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
EA026924B1 (ru) * | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
US8956619B2 (en) | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
ES2816647T3 (es) | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
CA2899433A1 (en) | 2012-01-27 | 2013-08-01 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
MX370265B (es) | 2012-05-25 | 2019-12-09 | Cellectis | Métodos para manipular por ingeniería genética célula t alogénica y resistente a inmunosupresores para inmunoterapia. |
JP6403166B2 (ja) * | 2012-08-03 | 2018-10-10 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 単一抗原抗pd−l1およびpd−l2二重結合抗体およびその使用方法 |
EP3597215A1 (en) | 2012-10-02 | 2020-01-22 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
EP4116331A1 (en) | 2012-12-17 | 2023-01-11 | PF Argentum IP Holdings LLC | Treatment of cd47+ disease cells with sirp alpha-fc fusions |
US20150368316A1 (en) | 2013-02-07 | 2015-12-24 | Albert Einstein College Of Medicine Of Yeshiva University | A selective high-affinity immune stimulatory reagent and uses thereof |
RU2680010C2 (ru) | 2013-02-26 | 2019-02-14 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы иммунотерапии |
WO2016022994A2 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
WO2016187226A1 (en) * | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
-
2015
- 2015-08-07 WO PCT/US2015/044356 patent/WO2016022994A2/en active Application Filing
- 2015-08-07 CA CA2994927A patent/CA2994927A1/en active Pending
- 2015-08-07 ES ES15829652T patent/ES2819451T3/es active Active
- 2015-08-07 PL PL15829652T patent/PL3177640T3/pl unknown
- 2015-08-07 EP EP15829652.5A patent/EP3177640B1/en active Active
- 2015-08-07 EP EP20166891.0A patent/EP3699189A1/en active Pending
- 2015-08-07 JP JP2017505807A patent/JP6945444B2/ja active Active
- 2015-08-07 PT PT158296525T patent/PT3177640T/pt unknown
- 2015-08-07 DK DK15829652.5T patent/DK3177640T3/da active
- 2015-08-07 CN CN201580054333.5A patent/CN107108707A/zh active Pending
- 2015-08-07 US US14/821,589 patent/US9546206B2/en active Active
- 2015-08-07 US US15/502,439 patent/US10800830B2/en active Active
- 2015-08-07 HU HUE15829652A patent/HUE050406T2/hu unknown
- 2015-11-03 US US14/931,725 patent/US9562087B2/en active Active
-
2020
- 2020-05-26 US US16/883,396 patent/US11814419B2/en active Active
- 2020-07-23 HR HRP20201153TT patent/HRP20201153T1/hr unknown
- 2020-08-05 CY CY20201100728T patent/CY1123385T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US20210040176A1 (en) | 2021-02-11 |
EP3177640B1 (en) | 2020-05-06 |
JP6945444B2 (ja) | 2021-10-06 |
EP3177640A4 (en) | 2018-01-03 |
US20160052990A1 (en) | 2016-02-25 |
DK3177640T3 (da) | 2020-08-10 |
HUE050406T2 (hu) | 2020-12-28 |
WO2016022994A2 (en) | 2016-02-11 |
US20160039903A1 (en) | 2016-02-11 |
US10800830B2 (en) | 2020-10-13 |
CN107108707A (zh) | 2017-08-29 |
WO2016022994A9 (en) | 2017-05-11 |
US20170233451A1 (en) | 2017-08-17 |
PT3177640T (pt) | 2020-08-31 |
WO2016022994A3 (en) | 2016-05-06 |
EP3177640A2 (en) | 2017-06-14 |
ES2819451T3 (es) | 2021-04-16 |
US9546206B2 (en) | 2017-01-17 |
HRP20201153T1 (hr) | 2021-01-22 |
JP2017525354A (ja) | 2017-09-07 |
CA2994927A1 (en) | 2016-02-11 |
US9562087B2 (en) | 2017-02-07 |
EP3699189A1 (en) | 2020-08-26 |
CY1123385T1 (el) | 2021-12-31 |
US11814419B2 (en) | 2023-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286316A (en) | New micro-dystrophins and related method of use | |
PL3177640T3 (pl) | Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania | |
IL250415B (en) | Antibodies against pd-l and methods of using them | |
HK1243102A1 (zh) | 抗cd79b抗體和使用方法 | |
HRP20181359T1 (hr) | Anti-jagged1 protutijela i postupci uporabe | |
IL251868A0 (en) | Anti-tim3 antibodies and methods of use | |
HK1253049A1 (zh) | 糖基相互作用化合物及其使用方法 | |
IL251988A0 (en) | Compounds acting on glycans and methods of using them | |
IL251165A0 (en) | Anti-il-1beta antibodies and methods of their use | |
ZA201701909B (en) | Trichoderma compositions and methods of use | |
SG11201708114SA (en) | Ophthalmic compositions and methods of use therefor | |
PL3089971T3 (pl) | Związki i sposoby ich zastosowania | |
IL251286A0 (en) | Anti-pdgf-b antibodies and methods of use | |
SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
ZA201606450B (en) | Compounds and their methods of use | |
HK1243404A1 (zh) | 色酰胺組合物和使用方法 | |
GB201403697D0 (en) | Compounds and methods of use | |
GB201416797D0 (en) | Contianer and method of use thereof |